* License to formulation technology with BDD Pharma, UK
** Contera Pharma has the first option right to enter exclusive worldwide license
# Small molecule
Recent News
August 28, 2025
Contera Pharma announces last patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal symptoms and morning akinesia in Parkinson’s disease
Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, today announced that the…
Read more
March 14, 2025
Contera Pharma announces that CP0014753, a novel antisense oligonucleotide developed for the treatment of Canavan disease, is ready for IND-enabling studies
Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the preclinical candidate nomination of CP0014753, a…
Read more
Contact us
Contera Pharma
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com